Lansoprazole enhances the antidiabetic effect of dapagliflozin in fortified diet-fed streptozotocin-treated diabetic rats.

Noha M Gamil Mai A Abd El Fattah Maha A E Ahmed Yousreya A Maklad Amina A Gamal El DinNihad I Eid

Published in: Journal of biochemical and molecular toxicology (2020)

Dapagliflozin (DAPA) is used for treating type 2 diabetes, whereas lansoprazole (LPZ) is used as a traditional antiulcer drug. The present study investigated the possible antidiabetic effects of LPZ on fortified diet-fed streptozotocin (FDF/STZ)-induced insulin-resistant diabetic rats. On the basis of the current results, it can be concluded that LPZ could be used as an add-on drug along with the conventional treatment for T2D as it showed beneficial effects in the current experimental model of insulin resistance.

Keyphrases

diabetic rats
type diabetes
oxidative stress
insulin resistance
glycemic control
weight loss
physical activity
adipose tissue
cardiovascular disease
high fat diet
metabolic syndrome
adverse drug
polycystic ovary syndrome
high resolution
mass spectrometry
electronic health record